dc.contributor.author | Samman, Nour | |
dc.contributor.author | Mohabatkar, Hassan | |
dc.contributor.author | Behbahani, Mandana | |
dc.contributor.author | Ganjlikhani Hakemi, Mazdak | |
dc.date.accessioned | 2024-07-02T05:33:42Z | |
dc.date.available | 2024-07-02T05:33:42Z | |
dc.date.issued | 2024 | en_US |
dc.identifier.citation | Samman, N., Mohabatkar, H., Behbahani, M. ve Ganjlikhani Hakemi, M. (2024). Bioinformatics design of a peptide vaccine containing sarcoma antigen NY-SAR-35 epitopes against breast cancer and evaluation of its immunological function in BALB/c mouse model. PloS One, 19(6). http://dx.doi.org/10.1371/journal.pone.0306117 | en_US |
dc.identifier.uri | http://dx.doi.org/10.1371/journal.pone.0306117 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/12682 | |
dc.description.abstract | The development of a cancer vaccine has become an essential focus in the field of medical biotechnology and immunology. In our study, the NY-SAR-35 cancer/testis antigen was targeted to design a novel peptide vaccine using bioinformatics tools, and BALB/c mice were used to evaluate the vaccine's immunological function. This evaluation involved assessing peptide-specific IgG levels in the serum via ELISA and measuring the levels of IFN-γ, IL-4, and granzyme B in the supernatant of cultured splenocytes. The final vaccine construct consisted of two T lymphocyte epitopes linked by the AAY linker. This construct displayed high antigenicity, non-allergenicity, non-toxicity, stability, and ability to induce IFN-γ and IL-4. It showed stable dynamics with both human MHC-I and II molecules, as well as mouse MHC-II molecules, and revealed strong Van der Waals and electrostatic energies. Emulsifying our peptide vaccine in incomplete Freund's adjuvant resulted in a remarkable increase in the levels of IgG. The splenocytes of mice that received the combination of peptide and adjuvant displayed a noteworthy increase in IFN-γ, IL-4, and granzyme B secretion. Additionally, their lymphocytes exhibited higher proliferation rates compared to the control group. Our data demonstrated that our vaccine could stimulate a robust immune response, making it a promising candidate for cancer prevention. However, clinical trials are necessary to assess its efficacy in humans. | en_US |
dc.language.iso | eng | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Attribution 4.0 International | * |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | NY-SAR-35 | en_US |
dc.subject | TSAs | en_US |
dc.subject | TAAs | en_US |
dc.subject | Tumor-Specific Antigens | en_US |
dc.subject | Tumor-Associated Antigens | en_US |
dc.title | Bioinformatics design of a peptide vaccine containing sarcoma antigen NY-SAR-35 epitopes against breast cancer and evaluation of its immunological function in BALB/c mouse model | en_US |
dc.type | article | en_US |
dc.relation.ispartof | PloS One | en_US |
dc.department | İstanbul Medipol Üniversitesi, Rektörlük, Rejeneratif ve Restoratif Tıp Araştırmaları Merkezi (REMER) | en_US |
dc.department | İstanbul Medipol Üniversitesi, Rektörlük, Sağlık Bilim ve Teknolojileri Araştırma Enstitüsü | en_US |
dc.identifier.volume | 19 | en_US |
dc.identifier.issue | 6 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1371/journal.pone.0306117 | en_US |
dc.institutionauthor | Ganjlikhani Hakemi, Mazdak | |
dc.identifier.pmid | 38923980 | en_US |